TITAN PHARMACEUTICALS INC: Nasdaq/NYSE listing notice — Titan Pharmaceuticals receives Nasdaq extension to Oct 2, 2023 to regain compliance with $2.5M equity requirement

TITAN PHARMACEUTICALS INC

Stockholders' equity reported at $1.363M, below Nasdaq's $2.5M minimum.
Nasdaq grants 180-day extension to October 2, 2023 to demonstrate compliance.
Company submitted a compliance plan on May 22, 2023.
Failure to comply by Oct 2 or upon filing 2023 10-K may lead to delisting.
Delisting would reduce liquidity, market price, and access to financing.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

TITAN PHARMACEUTICALS INC received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

that a listed company’s stockholders’ equity be at least $2,500,000 (the “Stockholders’ Equity Requirement”). In its 2022 10-K, the Company reported stockholders’ equity of $1,363,000, and, as a result, does not currently satisfy the Stockholders’ Equity Requirement. The Company submitted a plan to regain compliance with the Stockholders’ Equity Requirement

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001829126-23-003950

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.